12:00 AM
May 13, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Elobixibat: Phase III started

Ferring began the double-blind, placebo-controlled, international Phase III Echo 1 and Echo 2 trials to evaluate 5 and 10 mg elobixibat daily in about 840 patients each. Patients will receive elobixibat for 26 weeks in Echo 1 and for 12 weeks followed by a 4-week withdrawal period...

Read the full 213 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >